Top Page
Evotec AG
(NASDAQ:EVO)
Evotec AG (EVO) vs. SPDR S&P 500 ETF (SPY)
Evotec AG Business Overview & Revenue Model
Evotec AG Earnings Call Summary
Evotec AG Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 756.33M | 796.97M | 781.43M | 751.45M | 618.03M | 500.92M |
| Gross Profit | 81.86M | 114.88M | 175.05M | 174.06M | 151.54M | 125.74M |
| EBITDA | -88.51M | -80.66M | 24.13M | -57.61M | 316.63M | 90.36M |
| Net Income | -158.98M | -196.08M | -83.91M | -175.66M | 215.51M | 6.28M |
Balance Sheet | ||||||
| Total Assets | 1.77B | 1.91B | 2.25B | 2.26B | 2.24B | 1.84B |
| Cash, Cash Equivalents and Short-Term Investments | 237.27M | 396.80M | 604.11M | 707.31M | 858.50M | 589.67M |
| Total Debt | 484.62M | 443.54M | 815.35M | 506.67M | 512.92M | 601.94M |
| Total Liabilities | 972.56M | 959.98M | 1.13B | 1.07B | 857.48M | 951.26M |
| Stockholders Equity | 800.14M | 952.52M | 1.12B | 1.19B | 1.38B | 886.41M |
Cash Flow | ||||||
| Free Cash Flow | -89.58M | -114.02M | -179.56M | 24.46M | 3.29M | -54.35M |
| Operating Cash Flow | 1.41M | 18.22M | 36.44M | 205.81M | 122.24M | 44.72M |
| Investing Cash Flow | -33.87M | -71.19M | -13.29M | -412.80M | -243.85M | -155.09M |
| Financing Cash Flow | -20.73M | -161.42M | 71.96M | -58.15M | 398.43M | 246.41M |
Evotec AG Technical Analysis
Evotec AG Risk Analysis
Evotec AG Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $1.22B | 11.75 | 14.84% | ― | -0.03% | -27.66% | |
72 Outperform | $1.45B | 28.58 | 22.96% | ― | 26.34% | -32.79% | |
66 Neutral | $1.84B | 50.20 | 7.83% | ― | 48.87% | ― | |
64 Neutral | $883.66M | 46.04 | 2.90% | ― | 3.14% | ― | |
55 Neutral | $2.76B | -141.31 | -1.86% | ― | 4.54% | -130.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $1.31B | -7.35 | -17.46% | ― | -1.19% | 5.06% |
Evotec AG Corporate Events
On 16 January 2026, Evotec SE reported that it had submitted several Notifications of Major Holdings to the German financial regulator BaFin, reflecting changes in significant shareholdings in the company earlier in the month. The filings detail that The Goldman Sachs Group, Inc. crossed a disclosure threshold on 13 January 2026, with its total position in Evotec amounting to 6.12% of voting rights when including both directly held shares and financial instruments, up from a previously reported 3.68%. These notifications signal a strengthened financial exposure by a major institutional investor and provide updated transparency to the market regarding Evotec’s shareholder structure, which may be of interest to existing shareholders and potential investors monitoring shifts in the company’s ownership base.
The most recent analyst rating on (EVO) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
On January 12 and 13, 2026, Evotec SE reported changes in significant shareholdings to the German financial regulator, reflecting updated notifications of major holdings by investors including entities associated with Michael Kaufman. The filings indicate that these investors now control a combined 5.03% of Evotec’s voting rights through shares and equity-swap instruments, a development that underscores a notable institutional stake in the company and may signal increased investor engagement in its future strategic direction.
The most recent analyst rating on (EVO) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
On 8 January 2026, Evotec SE announced that its Seattle-based subsidiary Just – Evotec Biologics received a new grant from the Gates Foundation to support AI-driven optimization of monoclonal antibodies and other biologics, using its J.MD molecular design suite. The funding will finance ten new J.MD projects over the next three years to enhance manufacturability, stability, pharmacokinetics and other developability attributes of biotherapeutics targeting multiple global health indications, with the aim of lowering costs and expanding access in low- and middle-income countries; the announcement underscores Evotec’s growing role in leveraging advanced biologics platforms for global health applications and extends a collaboration with the foundation that has already yielded multiple cGMP manufacturing campaigns for infectious disease antibodies. Separately, on the same date, Evotec submitted a Notification of Major Holdings to the German financial regulator, indicating ongoing capital markets activity and shareholder structure developments that may be relevant for investors monitoring the company’s ownership dynamics.
The most recent analyst rating on (EVO) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
On January 6, 2026, Evotec SE reported that it had submitted notifications of major holdings to the German financial regulator, Bundesanstalt für Finanzdienstleistungsaufsicht, after JPMorgan Chase & Co. crossed a relevant ownership threshold in the company on December 30, 2025. The filing shows that JPMorgan’s total voting interest in Evotec rose to 5.51%, comprising 3.06% of voting rights attached to shares and 2.45% via financial instruments, signaling increased exposure by a major U.S. financial institution and providing investors with updated transparency on Evotec’s shareholder structure.
The most recent analyst rating on (EVO) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
On January 1, 2026, Evotec SE announced the appointment of Dr. Sarah Fakih as Executive Vice President, Head of Global Communications and Investor Relations, a newly created role that integrates the company’s communications and investor relations functions. Reporting directly to CEO Dr. Christian Wojczewski and succeeding departing Investor Relations and ESG head Volker Braun, Dr. Fakih brings more than 15 years of life sciences experience and a capital markets and corporate messaging track record from senior roles at QIAGEN, MorphoSys and CureVac, a move aimed at sharpening Evotec’s strategic messaging, improving stakeholder engagement and reinforcing alignment around its scientific leadership and value creation narrative.
The most recent analyst rating on (EVO) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
On January 2, 2026, Evotec SE reported to the U.S. Securities and Exchange Commission that it had submitted Notifications of Major Holdings to the German financial regulator, in line with local transparency rules on significant shareholdings. The filings disclose that, as of December 24, 2025, JPMorgan Chase & Co.’s total voting interest in Evotec fell to 3.64%, down from 5.62%, combining direct shareholdings and financial instruments. This reduction in a major institutional holder’s stake may signal a shift in Evotec’s shareholder structure and could be relevant for investors monitoring changes in the company’s ownership and governance landscape.
The most recent analyst rating on (EVO) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
On December 8, 2025, Evotec SE announced the completion of its sale of the Just – Evotec Biologics Toulouse site to Sandoz AG, effective December 5, 2025. The transaction, valued at over $650 million, includes cash payments, technology license fees, and potential royalties on biosimilars. This move aligns with Evotec’s strategy to focus on its core strengths and transition to a scalable technology provider, enhancing its revenue mix and profit margins. The sale is expected to improve Evotec’s operational efficiency and support its growth in biologics manufacturing.
The most recent analyst rating on (EVO) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
On November 6, 2025, Evotec SE announced the implementation of a share repurchase program, intending to buy back up to 290,000 shares at a total cost of up to EUR 3,000,000. The program, set to run from November 7 to December 17, 2025, aims to convert repurchased shares into American Depositary Shares (ADS) for an employee share program. This strategic move is expected to enhance shareholder value and support employee retention, potentially strengthening Evotec’s market position.
The most recent analyst rating on (EVO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
On November 4, 2025, Evotec SE announced a significant agreement with Sandoz AG involving the sale of its Just – Evotec Biologics manufacturing site in Toulouse for approximately US$ 350 million in cash. The deal, which includes an indefinite technology license to Evotec’s continuous manufacturing platform, could potentially result in payments exceeding US$ 650 million plus royalties on a portfolio of up to ten biosimilar molecules. This transaction is expected to enhance Evotec’s revenue mix, profit margins, and capital efficiency, aligning with its strategy to transition to an asset-lighter business model. The agreement is seen as a transformative milestone for Evotec, enabling the company to expand its role as a scalable technology provider in the biologics manufacturing market.
The most recent analyst rating on (EVO) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.
On November 5, 2025, Evotec SE announced its financial results for the first nine months of 2025, highlighting a strategic shift in its revenue mix aimed at long-term growth. The company reported a decrease in group revenues by 7.1% to €535.1 million, primarily due to a 12.3% decline in the Discovery & Preclinical Development segment. However, Just – Evotec Biologics outperformed expectations with an 11.3% increase in revenues. Significant agreements were signed with Sandoz and Bristol Myers Squibb, potentially bringing substantial future revenues and royalties. Despite current challenges, Evotec confirmed its 2025 guidance and 2028 outlook, emphasizing strategic collaborations and cost reduction initiatives.
The most recent analyst rating on (EVO) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Evotec AG stock, see the EVO Stock Forecast page.